Equipment shortage and overpriced APIs pinch the pharma industry
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The medicine is now approved for eight indications across five different types of cancer in China.
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
Subscribe To Our Newsletter & Stay Updated